ABSTRACT
BACKGROUND: Lyme disease after a tick bite often presents as erythema migrans, yet less frequent variants of this disease, such as Borrelia lymphocytoma, multiple erythema migrans and neuroborreliosis, are also seen occasionally. CASE PRESENTATION: We report a case of a tick-bitten child who first presented with an indistinct macular erythema around the left eye and a more distinct macular erythema on and around the left ear. The next day, she developed a facial palsy. INTERPRETATION: The case was interpreted as facial multiple erythema migrans and Borrelia lymphocytoma on the ear, followed by neuroborreliosis. The diagnosis of lymphocytoma was made from clinical findings and PCR of skin biopsy. She recovered quickly after intravenous ceftriaxone and is now healthy.
Subject(s)
Lyme Disease , Pseudolymphoma , Skin Diseases, Bacterial , Child , Female , Humans , Ear Diseases/etiology , Erythema Chronicum Migrans/etiology , Facial Dermatoses/etiology , Facial Paralysis/etiology , Lyme Neuroborreliosis/etiology , Pseudolymphoma/diagnosis , Tick Bites/complications , Lyme Disease/complications , Lyme Disease/diagnosis , Skin Diseases, Bacterial/diagnosisABSTRACT
Neuroborreliosis (NB) and neurosyphilis (NS) are abnormal conditions caused by spirochetal bacteria which affect the nervous system. Diagnosis of neuroborreliosis and neurosyphilis is determined by clinical examination of visible symptoms, serum and cerebrospinal fluid (CSF) analysis, and serological detection of antibodies against Borrelia burgdorferi sensu lato and Treponema pallidum, respectively. Establishing a diagnosis may sometimes pose a number of diagnostic difficulties. A potential role of chemokine ligand 13 (CXCL13) as an accurate diagnostic biomarker of intrathecal inflammation has been suggested. In this review, we focused on changes in serum and cerebrospinal fluid concentration of chemokine ligand 13 in selected spirochetal neurological diseases neuroborreliosis and neurosyphilis reported in the available literature. We performed an extensive search of the literature relevant to our investigation via the MEDLINE/PubMed database. It has been proven that CXCL13 determination can provide rapid information regarding central nervous system inflammation in patients with selected spirochetosis. We described that neuroborreliosis and neurosyphilis are associated with an elevated CXCL13 concentration, mainly in the cerebrospinal fluid. Moreover, literature data suggest that CXCL13 determination is the most interesting additional marker for diagnosis and monitoring of neuroborreliosis and neurosyphilis thanks to its high sensitivity. Based on these published findings, we suggest that CXCL13 has high diagnostic utility and may be applied in laboratory diagnostics as a potential diagnostic marker in human spirochetal neurologic diseases.
Subject(s)
Biomarkers , Chemokine CXCL13/cerebrospinal fluid , Lyme Neuroborreliosis/cerebrospinal fluid , Lyme Neuroborreliosis/diagnosis , Neurosyphilis/cerebrospinal fluid , Neurosyphilis/diagnosis , Disease Management , Humans , Lyme Neuroborreliosis/etiology , Lyme Neuroborreliosis/therapy , Nervous System Diseases/cerebrospinal fluid , Nervous System Diseases/diagnosis , Nervous System Diseases/etiology , Neurosyphilis/etiology , Neurosyphilis/therapy , PrognosisABSTRACT
Some patients with a history of Borrelia burgdorferi infection develop a chronic symptomatology characterized by cognitive deficits, fatigue, and pain, despite antibiotic treatment. The pathogenic mechanism that underlines this condition, referred to as post-treatment Lyme disease syndrome (PTLDS), is currently unknown. A debate exists about whether PTLDS is due to persistent infection or to post-infectious damages in the immune system and the nervous system. We present the case of a patient with evidence of exposure to Borrelia burgdorferi sl and a long history of debilitating fatigue, cognitive abnormalities and autonomic nervous system issues. The patient had a positive Western blot for anti-basal ganglia antibodies, and the autoantigen has been identified as γ enolase, the neuron-specific isoenzyme of the glycolytic enzyme enolase. Assuming Borrelia own surface exposed enolase as the source of this autoantibody, through a mechanism of molecular mimicry, and given the absence of sera reactivity to α enolase, a bioinformatical analysis was carried out to identify a possible cross-reactive conformational B cell epitope, shared by Borrelia enolase and γ enolase, but not by α enolase. Taken that evidence, we hypothesize that this autoantibody interferes with glycolysis in neuronal cells, as the physiological basis for chronic symptoms in at least some cases of PTLDS. Studies investigating on the anti-γ enolase and anti-Borrelia enolase antibodies in PTLDS are needed to confirm our hypotheses.
Subject(s)
Borrelia burgdorferi/enzymology , Borrelia burgdorferi/immunology , Lyme Disease/immunology , Phosphopyruvate Hydratase/immunology , Adult , Antibodies, Bacterial/blood , Antigens, Bacterial/chemistry , Antigens, Bacterial/genetics , Autoantibodies/blood , Autoimmunity , Borrelia burgdorferi/pathogenicity , Cross Reactions , Epitopes, B-Lymphocyte/chemistry , Epitopes, B-Lymphocyte/genetics , Epitopes, B-Lymphocyte/immunology , Glycolysis/immunology , Humans , Lyme Disease/etiology , Lyme Disease/microbiology , Lyme Neuroborreliosis/etiology , Lyme Neuroborreliosis/immunology , Lyme Neuroborreliosis/microbiology , Male , Models, Immunological , Molecular Mimicry/immunology , Phosphopyruvate Hydratase/chemistry , Phosphopyruvate Hydratase/genetics , Protein ConformationABSTRACT
We describe here treatment approaches and treatment-related complications in 138 hospitalized children with disseminated Lyme disease. The patients who received parenteral antibiotics had a higher rate of complications than those who received oral therapy (15.4 vs 4.2 per 1000 days of therapy, respectively; P < .05). Oral therapy should be used preferentially if either route is supported by current guidelines.
Subject(s)
Lyme Disease/complications , Administration, Oral , Anti-Bacterial Agents/administration & dosage , Anti-Bacterial Agents/therapeutic use , Child , Hospitalization , Humans , Infusions, Parenteral , Lyme Disease/therapy , Lyme Neuroborreliosis/etiology , Lyme Neuroborreliosis/therapyABSTRACT
Lyme borreliosis is a tick-borne disease that predominantly occurs in temperate regions of the northern hemisphere and is primarily caused by the bacterium Borrelia burgdorferi in North America and Borrelia afzelii or Borrelia garinii in Europe and Asia. Infection usually begins with an expanding skin lesion, known as erythema migrans (referred to as stage 1), which, if untreated, can be followed by early disseminated infection, particularly neurological abnormalities (stage 2), and by late infection, especially arthritis in North America or acrodermatitis chronica atrophicans in Europe (stage 3). However, the disease can present with any of these manifestations. During infection, the bacteria migrate through the host tissues, adhere to certain cells and can evade immune clearance. Yet, these organisms are eventually killed by both innate and adaptive immune responses and most inflammatory manifestations of the infection resolve. Except for patients with erythema migrans, Lyme borreliosis is diagnosed based on a characteristic clinical constellation of signs and symptoms with serological confirmation of infection. All manifestations of the infection can usually be treated with appropriate antibiotic regimens, but the disease can be followed by post-infectious sequelae in some patients. Prevention of Lyme borreliosis primarily involves the avoidance of tick bites by personal protective measures.
Subject(s)
Lyme Disease/diagnosis , Lyme Disease/physiopathology , Amoxicillin/pharmacology , Amoxicillin/therapeutic use , Animals , Anti-Bacterial Agents/pharmacology , Anti-Bacterial Agents/therapeutic use , Borrelia burgdorferi/immunology , Borrelia burgdorferi/pathogenicity , Borrelia burgdorferi Group/immunology , Borrelia burgdorferi Group/pathogenicity , Cefuroxime/analogs & derivatives , Cefuroxime/pharmacology , Cefuroxime/therapeutic use , Doxycycline/pharmacology , Doxycycline/therapeutic use , Exanthema/etiology , Humans , Ixodes/microbiology , Lyme Disease/epidemiology , Lyme Neuroborreliosis/complications , Lyme Neuroborreliosis/etiology , Lyme Neuroborreliosis/physiopathology , Risk Factors , Zoonoses/etiology , Zoonoses/microbiology , beta-Lactams/pharmacology , beta-Lactams/therapeutic useABSTRACT
Nervous system involvement occurs in 10% to 15% of patients infected with the tick-borne spirochetes Borrelia burgdorferi, B afzelii, and B garinii. Peripheral nervous system involvement is common. Central nervous system (CNS) involvement, most commonly presenting with lymphocytic meningitis, causes modest cerebrospinal fluid (CSF) pleocytosis. Parenchymal CNS infection is rare. If the CNS is invaded, however, measuring local production of anti-B burgdorferi antibodies in the CSF provides a useful marker of infection. Most cases of neuroborreliosis can be cured with oral doxycycline; parenteral regimens should be reserved for patients with particularly severe disease.
Subject(s)
Lyme Neuroborreliosis , Animals , Antibodies, Bacterial/cerebrospinal fluid , Doxycycline/therapeutic use , Humans , Lyme Neuroborreliosis/complications , Lyme Neuroborreliosis/diagnosis , Lyme Neuroborreliosis/drug therapy , Lyme Neuroborreliosis/etiologyABSTRACT
No disponible
Subject(s)
Humans , Female , Infant , Lyme Neuroborreliosis/complications , Lyme Neuroborreliosis/etiology , Lyme Neuroborreliosis/pathology , Lyme Neuroborreliosis/therapy , Hypoglossal Nerve/pathology , Vagus Nerve/pathology , Facial Paralysis/complications , Facial Paralysis/pathology , Meningitis, Aseptic/complications , Meningitis, Aseptic/pathology , Leukocytosis/cerebrospinal fluid , Leukocytosis/pathology , Dysphonia/complications , Sialorrhea/complications , Spinal PunctureABSTRACT
The Lyme disease controversy can be largely linked to the misconception that neurobehavioral effects of illness constitute evidence of nervous system infection. Appropriate differentiation between neuroborreliosis (nervous system Borrelia burgdorferi infection) and Lyme encephalopathy (altered nervous system function in individuals with systemic but not nervous system infection)-or encephalopathies of other etiologies-would lessen the controversy considerably, as the attribution of nonspecific symptoms to supposed ongoing central nervous system infection is a major factor perpetuating the debate. Epidemiologic considerations suggest that the entities referred to as "posttreatment Lyme disease" and "chronic Lyme disease" may not actually exist but rather reflect anchoring bias, linking common, nonspecific symptoms to an antecedent medical event. On the other hand, there are data suggesting possible mechanisms by which posttreatment Lyme disease could occur.
Subject(s)
Lyme Disease/diagnosis , Lyme Neuroborreliosis/diagnosis , Behavior , Humans , Lyme Disease/complications , Lyme Disease/pathology , Lyme Neuroborreliosis/etiology , Lyme Neuroborreliosis/pathologyABSTRACT
Lyme neuroborreliosis (LNB) designates the nervous system disorders caused by the tick-borne spirochete Borrelia burgdorferi (Bb). The clinical syndromes are usually distinct and are classified as early and the rare late or chronic LNB. Early LNB occurs 3-6 weeks after infection most frequently as a lymphocytic meningoradiculoneuritis (LMR). Symptoms are mainly due to a painful sensory radiculitis and a multifocal motor radiculo-neuritis. Fifty percent have cranial nerve involvement predominantly uni- or bilateral facial nerve palsies. Meningitic symptoms occur primarily in children. Nerve biopsies, autopsies, animal models, and nerve conduction studies showed that the pathology is a lymphocytic perineuritis leading to multisegmental axonal injury of nerve roots, spinal ganglia, and distal nerve segments. Due to meningeal and root inflammation cerebrospinal fluid (CSF) shows lymphocytic inflammation. The only evidence that Bb causes peripheral neuropathy without CSF inflammation is seen in patients with acrodermatitis chronica atrophicans (ACA), a chronic dermatoborreliosis. In the rare chronic or late LNB the pathology and thus the clinical presentation is primarily due to chronic meningitis and meningovascular CNS involvement, whereas the peripheral nervous system is not primarily affected. In early and late LNB the diagnosis is based on a characteristic clinical appearance and CSF inflammation with Bb-specific intrathecal antibody production. Both conditions, but not the ACA-associated neuropathy, respond to antibiotic therapy.
Subject(s)
Borrelia/pathogenicity , Lyme Neuroborreliosis , Humans , Lyme Neuroborreliosis/epidemiology , Lyme Neuroborreliosis/etiology , Sural Nerve/pathologyABSTRACT
Lyme disease, infection with Borrelia burgdorferi, is a focally endemic tick-transmitted zoonosis. During the 3 decades since the responsible spirochete was identified, a series of misconceptions and misunderstandings have become widely prevalent, leading to frequent misdiagnosis and inappropriate treatment. Persistent misconceptions concern the reliability of available diagnostic tools, the signs and symptoms of nervous system involvement, the appropriate choice and duration of antimicrobial therapy, the curability of the infection, and the cause of symptoms that may persist in some patients after treatment. Concern about disparate perspectives led the Institute of Medicine to review the subject. In this article we review the principal misconceptions, discussing their origins and the best currently available scientific evidence related to each one.
Subject(s)
Lyme Disease/diagnosis , Anti-Bacterial Agents/administration & dosage , Anti-Bacterial Agents/therapeutic use , Cognition Disorders/etiology , Erythema Chronicum Migrans/diagnosis , Erythema Chronicum Migrans/etiology , False Negative Reactions , False Positive Reactions , Fatigue/etiology , Humans , Lyme Disease/complications , Lyme Disease/drug therapy , Lyme Neuroborreliosis/diagnosis , Lyme Neuroborreliosis/etiology , Serologic TestsABSTRACT
OBJECTIVE: Patients with chronic neurological disorders and cognitive impairment after tick bites are difficult to manage despite standard antibiotic therapy for Lyme disease. We wanted to correctly assess the disorders. METHODS: Thirty patients were hospitalized for a standardized evaluation of their disorders: clinical examination, biological and serological studies, cerebral MRI, CSF study, neurophysiological exams, and neuropsychological evaluation of cognitive functions. RESULTS: Clinical and biological results were non informative. We observed significant CSF abnormalities (64%), MRI Flair pictures (41%), neurophysiological exams (47%), and cognitive evaluation (100%). CONCLUSIONS: A large and standardized evaluation should be made for each patient to improve the management and probably the treatment of these complex chronic symptoms observed after tick bites.
Subject(s)
Arachnid Vectors , Bites and Stings/complications , Cognition Disorders/epidemiology , Lyme Neuroborreliosis/epidemiology , Nervous System Diseases/epidemiology , Ticks , Adult , Aged , Animals , Anti-Bacterial Agents/therapeutic use , Arachnid Vectors/microbiology , Autoimmune Diseases of the Nervous System/epidemiology , Autoimmune Diseases of the Nervous System/etiology , Bites and Stings/epidemiology , Bites and Stings/microbiology , Cerebrospinal Fluid Proteins/analysis , Cognition Disorders/etiology , Electroencephalography , Evoked Potentials , Female , France/epidemiology , Humans , Lyme Neuroborreliosis/cerebrospinal fluid , Lyme Neuroborreliosis/diagnosis , Lyme Neuroborreliosis/drug therapy , Lyme Neuroborreliosis/etiology , Magnetic Resonance Imaging , Male , Middle Aged , Nervous System Diseases/etiology , Neuropsychological Tests , Prospective Studies , Seroepidemiologic Studies , Ticks/microbiologyABSTRACT
OBJECTIVES: To survey present knowledge and controversies in European neuroborreliosis. MATERIAL AND METHODS: The article is based on available literature, own experience, and a speech held by the authors. together on the Norwegian annual neurological meeting. RESULTS: Diagnosis of neuroborreliosis is based on clinical neurological findings, laboratory support of borrelia infection, and indications of causality between neurological findings and borreliosis. In the absence of means to identify B. burgdorferi, antibody tests are used for laboratory diagnosis. Two to three weeks courses of IV penicillin or ceftriaxone are highly effective in neuroborreliosis. Oral doxycyclin is probably equally effective. Remaining symptoms five years after treatment for neuroborreliosis are reported in 25-50% of patients. CONCLUSIONS: We suggest two levels of diagnostic accuracy; definite and possible neuroborreliosis. These case definitions are proposed to make the basis for treatment decisions. The prognosis of neuroborreliosis and pathophysiology of post-treatment conditions need further studies. Extensive treatments with antibiotics are not recommended.
Subject(s)
Lyme Neuroborreliosis/diagnosis , Lyme Neuroborreliosis/therapy , Adult , Anti-Bacterial Agents/therapeutic use , Drug Administration Schedule , Europe , Humans , Lyme Neuroborreliosis/etiology , PrognosisABSTRACT
Lyme neuroborreliosis (LNB), the neurological manifestation of systemic infection with the complex spirochaete Borrelia burgdorferi, can pose a challenge for practising neurologists. This Review is a summary of clinical presentation, diagnosis, and therapy, as well as of recent advances in our understanding of LNB. Many new insights have been gained through work in experimental models of the disease. An appreciation of the genetic heterogeneity of the causative pathogen has helped clinicians in their understanding of the diverse presentations of LNB.
Subject(s)
Borrelia/pathogenicity , Immunity , Infections/complications , Inflammation , Lyme Neuroborreliosis/complications , Lyme Neuroborreliosis/etiology , Animals , Humans , Lyme Disease Vaccines , Lyme Neuroborreliosis/epidemiologyABSTRACT
We report on a patient who developed seronegative Lyme neuroborreliosis complicating chemotherapy for chronic lymphatic leukemia. After the fifth cycle of chemotherapy (FCR: fludarabine, cyclophosphamide, rituximab and prednisone) the 63-year-old patient developed night sweat, arthralgia in elbows, wrists, proximal interphalangeal joints (PIPs) and strong neuropathic pain in both legs, followed by paresthesia and hypesthesia in the feet, arms and face. Laboratory analysis revealed an elevated C-reactive protein (CRP), a slight elevation of liver enzymes and decreased IgG levels. Cerebrospinal fluid (CSF) analysis showed a lymphomononuclear pleocytosis and an elevation of protein. A broad diagnostic work-up was negative including a negative Borrelia IgG and IgM ELISA. The patient did not remember recent tick bites, but after specific questioning he recollected a transient erythema on his leg developing just before the start of the last cycle of chemotherapy. As the combination of neuropathic pain and arthralgia, the transient erythema and the lymphomononuclear pleocytosis raised the suspicion of Lyme neuroborreliosis, the patient was treated for 3 weeks with ceftriaxone. On therapy all symptoms resolved and CRP normalized. Retrospective PCR analysis of a CSF sample confirmed the clinical diagnosis by detecting Borrelia garinii DNA. This case demonstrates that in immunosuppressed patients borrelial serology may be negative and that additional diagnostic approaches (including tests for direct Borrelia detection) may be needed to demonstrate borrelial infection.
Subject(s)
Antineoplastic Combined Chemotherapy Protocols/adverse effects , Borrelia burgdorferi Group/isolation & purification , Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy , Lyme Neuroborreliosis/etiology , Antibodies, Bacterial/blood , DNA, Bacterial/analysis , Humans , Lyme Neuroborreliosis/diagnosis , Male , Middle Aged , Polymerase Chain ReactionSubject(s)
Lyme Neuroborreliosis/therapy , Meningoencephalitis/therapy , Animals , Diagnosis, Differential , Humans , Lyme Neuroborreliosis/diagnosis , Lyme Neuroborreliosis/epidemiology , Lyme Neuroborreliosis/etiology , Lyme Neuroborreliosis/microbiology , Meningoencephalitis/diagnosis , Meningoencephalitis/epidemiology , Meningoencephalitis/etiology , Meningoencephalitis/microbiology , PrognosisABSTRACT
We describe a patient with a history of allogeneic hematopoietic stem cell transplantation complicated by chronic graft-versus-host disease who developed painful meningoradiculitis and myositis due to Lyme borreliosis. To our knowledge, this is the first report of such an infection occurring after allogeneic hematopoietic stem cell transplantation in the United States.
Subject(s)
Hematopoietic Stem Cell Transplantation/adverse effects , Lyme Disease/etiology , Lyme Neuroborreliosis/etiology , Myositis/etiology , Adult , Humans , Male , Myositis/microbiologyABSTRACT
Brain invasion by Borrelia burgdorferi, the agent of Lyme disease, results in an inflammatory and neurodegenerative disorder called neuroborreliosis. In humans, neuroborreliosis has been correlated with enhanced concentration of glial fibrillary acidic protein in the cerebrospinal fluid, a sign of astrogliosis. Rhesus monkeys infected by us with B. burgdorferi showed evidence of astrogliosis, namely astrocyte proliferation and apoptosis. We formulated the hypothesis that astrogliosis could be caused by spirochetal lipoproteins. We established primary cultures of rhesus monkey astrocytes and stimulated the cells with recombinant lipidated outer surface protein A (L-OspA), a model B. burgdorferi lipoprotein, and tripalmitoyl-S-glyceryl-Cys-Ser-Lys(4)-OH (Pam(3)Cys), a synthetic lipopeptide that mimics the structure of the lipoprotein lipid moiety. L-OspA elicited not only astrocyte proliferation but also apoptosis, two features observed during astrogliosis. Astrocytes produced both IL-6 and TNF-alpha in response to L-OspA and Pam(3)Cys. Proliferation induced by L-OspA was diminished in the presence of an excess of anti-IL-6 antibody, and apoptosis induced by this lipoprotein was completely suppressed with anti-TNF-alpha antibody. Hence, IL-6 contributes to, and TNF-alpha determines, astrocyte proliferation and apoptosis, respectively, as elicited by lipoproteins. Our results provide proof of the principle that spirochetal lipoproteins could be key virulence factors in Lyme neuroborreliosis, and that astrogliosis might contribute to neuroborreliosis pathogenesis.